Trials / Terminated
TerminatedNCT02241720
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | regorafenib |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2014-09-16
- Last updated
- 2018-01-11
- Results posted
- 2017-10-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02241720. Inclusion in this directory is not an endorsement.